Anti-depressant effect of curcumin-loaded guanidine-chitosan thermo-sensitive hydrogel by nasal delivery

Qi, Xue-Jie; Liu, Xiangyun; Tang, Lei-Meng-Yuan; Li, Pan-Feng; Qiu, Feng; Yang, Ai-Hong

doi:10.1080/10837450.2019.1686524

Cited by 38 publications

(14 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kulkarni et al (16) had similar results in a study on rats in which curcumin dose-dependently increased serotonin and dopamine as well as inhibited the monoamine oxidase enzymes. More recent studies also showed that curcumin could elevate norepinephrine, serotonin, and dopamine in the frontal cortex, hippocampus, and striatum in rats (17)(18)(19)(20)(21)(22).…”

Section: Curcumin and Monoaminesmentioning

confidence: 93%

Curcumin in Depression: Potential Mechanisms of Action and Current Evidence—A Narrative Review

2020

View full text Add to dashboard Cite

Major depressive disorder (MDD) is one of the most prevalent and debilitating disorders. Current available treatments are somehow limited, so alternative therapeutic approaches targeting different biological pathways are being investigated to improve treatment outcomes. Curcumin is the main active component in the spice turmeric that has been used for centuries in Ayurvedic medicine to treat a variety of conditions, including anxiety and depressive disorders. In the past decades, curcumin has drawn researchers' attention and displays a broad range of properties that seem relevant to depression pathophysiology. In this review, we break down the potential mechanisms of action of curcumin with emphasis on the diverse systems that can be disrupted in MDD. Curcumin has displayed, in a number of studies, a potency in modulating neurotransmitter concentrations, inflammatory pathways, excitotoxicity, neuroplasticity, hypothalamic–pituitary–adrenal disturbances, insulin resistance, oxidative and nitrosative stress, and endocannabinoid system, all of which can be involved in MDD pathophysiology. To date, a handful of clinical trials have been published and suggest a benefit of curcumin in MDD. With evidence that is progressively growing, curcumin appears as a promising alternative option in the management of MDD.

show abstract

Section: Curcumin and Monoaminesmentioning

confidence: 93%

Curcumin in Depression: Potential Mechanisms of Action and Current Evidence—A Narrative Review

2020

View full text Add to dashboard Cite

show abstract

“…Twenty studies reported an increment of 5-HT levels in the hippocampus, striatum or frontal cortex, which may be due to the interaction found between curcumin and 5-HT/cAMP/PKA/CREB/BDNF-signaling pathway or 5-HT 1A/1B and 5-HT 2C receptors [ 35 , 40 , 80 , 83 , 85 , 90 ]. Besides, fifteen studies reported an increased level of DA [ 38 , 41 , 42 , 44 , 45 , 46 , 48 , 49 , 55 , 72 , 77 , 81 , 87 , 91 ]. NA was also incremented in five studies [ 46 , 49 , 55 , 63 , 86 ].…”

Section: Resultsmentioning

confidence: 99%

An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders

et al. 2022

View full text Add to dashboard Cite

Curcumin is a polyphenol extracted from the rhizome of the turmeric plant. Beyond its common use as a culinary spice in Eastern Asia, curcumin has been proposed as a therapeutic compound due to its antioxidant, anti-inflammatory and neuroprotective properties. Thus, its efficacy has been evaluated in various inflammatory-based psychiatric disorders, such as schizophrenia, depression, or autism. Our aim is to review those preclinical and clinical studies carried out in psychiatric disorders whose therapeutic approach has involved the use of curcumin and, therefore, to discern the possible positive effect of curcumin in these disorders. Preclinical studies and completed clinical trials of curcumin for psychiatric disorders published from January 2005 to October 2021 were identified through searching relevant databases until 31st October 2021. Sixty-five preclinical studies and 15 clinical trials and open-label studies were selected. Results showed a bias toward studies in depression and, to a lesser extent, schizophrenia. In all disorders, the results were positive in reducing psychiatric deficits. Despite the considerable number of beneficial outcomes reported, the small number of trials and the heterogeneity of protocols make it difficult to draw solid conclusions about the real potency of curcumin in psychiatric disorders.

show abstract

“…Even though the benefits of curcumin, its use is limited by its low oral bioavailability and distribution. One possibility to solve this problem is the curcumin in nanoparticles, liposomes, micelles, and phospholipid complexes formulations (Asadi et al, 2019; Qi et al, 2020; Yohn et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

“…The authors found an increase in the concentration of norepinephrine (NE), dopamine (DA), and 5-Hydroxytryptamine (5-HT) and their metabolites. They concluded that the formulation of curcumin by nasal delivery is useful in the treatment of depression, showing an acceptable form of administration (Qi et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

A systematic review of the antidepressant effects of curcumin: Beyond monoamines theory

Matias

Achete

Campanari

et al. 2021

Aust N Z J Psychiatry

View full text Add to dashboard Cite

Background: Depression is a severe, chronic, and recurring mental health disorder, which prevalence and morbimortality have increased in recent years. Several theories are proposed to elucidate the mechanisms of depression, such as the involvement of inflammation and the release of cytokines. Alternative treatments have been developed to improve outcomes of the commonly used drugs, and the use of Curcuma longa stands out. Its primary compound is named curcumin that exhibits antioxidant and anti-inflammatory effects. Aims: Several studies have shown that curcumin may play antidepressant actions and, therefore, this study aimed to perform a systematic review of the antidepressant effects of curcumin to evaluate the impact of this compound in the treatment of this condition. Methods: This systematic review has included studies available in MEDLINE–PubMed, EMBASE, and Cochrane databases, and the final selection included 10 randomized clinical trials. Conclusion: Curcumin improves depressant and anxiety behavior in humans. It can increase monoamines and brain-derived neurotrophic factor levels and may inhibit the production of pro-inflammatory cytokines and neuronal apoptosis in the brain. Systemically, curcumin enhanced insulin sensitivity, reduced cortisol levels, and reversed metabolic abnormalities. Studies with larger samples and standardized dose and formulation are required to demonstrate the benefits of curcumin in depression treatment since there are many variations in this compound’s use.

show abstract

Anti-depressant effect of curcumin-loaded guanidine-chitosan thermo-sensitive hydrogel by nasal delivery

Cited by 38 publications

References 43 publications

Curcumin in Depression: Potential Mechanisms of Action and Current Evidence—A Narrative Review

Curcumin in Depression: Potential Mechanisms of Action and Current Evidence—A Narrative Review

An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders

A systematic review of the antidepressant effects of curcumin: Beyond monoamines theory

Contact Info

Product

Resources

About